$62.00
0.00% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US1717571079
Symbol
CDTX

Cidara Therapeutics, Inc. Stock price

$62.00
+6.68 12.08% 1M
+38.54 164.22% 6M
+35.12 130.65% YTD
+50.28 428.78% 1Y
+49.30 388.19% 3Y
-13.60 17.99% 5Y
-210.00 77.21% 10Y
-258.00 80.63% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.00%
ISIN
US1717571079
Symbol
CDTX
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.4b
Net debt
positive
Cash
$168.2m
Shares outstanding
12.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5,240.7 | -
EV/Sales
4,680.2 | -
EV/FCF
negative
P/B
11.1
Financial Health
Equity Ratio
76.0%
Return on Equity
-104.0%
ROCE
-134.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$300.0k | $0.0
EBITDA
$-192.6m | $-126.9m
EBIT
$-192.8m | $-130.3m
Net Income
$-183.0m | $-99.0m
Free Cash Flow
$-192.0m
Growth (TTM | estimate)
Revenue
-99.4% | -100.0%
EBITDA
-406.7% | -39.5%
EBIT
-405.4% | -42.8%
Net Income
-401.7% | 41.7%
Free Cash Flow
-931.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-63,775.8% | -
EBIT
-63,850.7%
Net
-60,589.7% | -
Free Cash Flow
-63,558.0%
More
EPS
$-12.9
FCF per Share
$-15.7
Short interest
10.3%
Employees
38
Rev per Employee
$30.0k
Show more

Is Cidara Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Cidara Therapeutics, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.30 0.30
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
16% 16%
7,733%
- Research and Development Expense 91 91
47% 47%
30,187%
-193 -193
407% 407%
-64,200%
- Depreciation and Amortization 0.23 0.23
64% 64%
77%
EBIT (Operating Income) EBIT -193 -193
405% 405%
-64,276%
Net Profit -183 -183
402% 402%
-60,993%

In millions USD.

Don't miss a Thing! We will send you all news about Cidara Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cidara Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.
Positive
The Motley Fool
5 days ago
Cidara (CDTX) Q2 Cash Surges 163%
Neutral
GlobeNewsWire
5 days ago
Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA) Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for ...
More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Jeffrey Stein
Employees 38
Founded 2012
Website www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today